“The increase in Age-related Macular Degeneration market size is a direct consequence of an increase in R&D activity, increasing prevalent population, expected commercial success of upcoming therapies in the 7MM”

 

The Age-related Macular Degeneration Market is expected to gain market growth in the forecast period of 2022 to 2032. The growing cases of tumors will directly impact the growth of the Age-related Macular Degeneration market

 

The Age-related Macular Degeneration Market Insights report from DelveInsight provides a thorough understanding of current therapeutic approaches, emerging medications, Age-related Macular Degeneration market share of particular therapies, and current and projected market sizes from 2019 to 2032, divided into the 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

 

Key highlights from the Age-related Macular Degeneration Market Report

• The Age-related Macular Degeneration Market size is anticipated to increase during the study period, 2019–2032
• As per DelveInsight analysis, the Age-related macular degeneration market size in the 7MM was approximately USD 9.8 billion in 2021.
• As per DelveInsight estimation, the Dry AMD market size was approximately USD 1,377 million, and the Wet AMD market size was approximately USD 8,463 million, which is further expected to increase by 2032.
• Age-related Macular Degeneration Market Companies included such as Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics Inc., Unity Biotechnology Inc, PanOptica Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics and Novartis, Luxa Biotechnology, Gemini Therapeutics, and several others

 

Interested to know more about the ongoing developments in the Age-related Macular Degeneration Market Report? Visit here- Age-related Macular Degeneration Market Outlook

 

Age-related macular degeneration Overview

Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries around the world, with a significant impact on the quality of life of the affected people. With the current expensive standard of care, the increase in Age-related macular degeneration life expectancy brings an increase in the number of reported cases, putting major stress on health care systems. Age-related macular degeneration (AMD) can also be characterized as either dry Age-related macular degeneration (atrophic or non-neovascular) or wet Age-related macular degeneration (exudative or neovascular).

 

Age-related Macular Degeneration Epidemiology Segmentation in the 7MM

• Total Age-related Macular Degeneration Prevalent Cases
• Total Age-related Macular Degeneration Diagnosed Prevalent Cases
• Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases
• Total Age-related Macular Degeneration Age-specific Cases
• Total Age-related Macular Degeneration Diagnosed Dry AMD Cases by Stages
• Total Age-related Macular Degeneration Geographic Atrophy Cases Associated With Dry AMD by Visual Impairment

 

Age-related Macular Degeneration Treatment Market

Photodynamic therapy, which employed an intravenous drug (injected into a vein) and laser to seal off bleeding blood vessels, was the best available Age-related macular degeneration treatment fifteen years ago. However, improvements in medical research have revealed VEGF as a critical pathophysiological factor in the development of neovascular AMD, with an important involvement in angiogenesis, vascular permeability, and inflammatory response. Anti-VEGF intravitreal injections have provided a new therapeutic window in the wet AMD treatment, effectively stopping the pathophysiological process of AMD and restoring retinal shape and function.

 

Discover more relevant information on the Age-related Macular Degeneration Market Research Report here- Age-related Macular Degeneration Market Size

 

Age-related Macular Degeneration Market Growth

The Age-related macular degeneration market growth is expected to boost owing to the expected launch of therapies, increasing prevalence of Age-related macular degeneration, development in the field of gene therapy, patient-friendly dosage regimes, and several other factors during the forecast period.

 

Age-related Macular Degeneration Therapeutics Market

The most common Age-related macular degeneration symptoms include blurry or fuzzy vision, loss of central vision, difficulty in recognizing familiar faces, and others. Visual acuity test, pupil dilation, fluorescein angiography, Amsler grid, and others are the following tests used for Age-related macular degeneration diagnosis.

 

Scope of the Age-related Macular Degeneration Market Report

• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2022-2032
• Age-related Macular Degeneration Market Companies- Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics Inc., Unity Biotechnology Inc, PanOptica Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics and Novartis, Luxa Biotechnology, Gemini Therapeutics, and several others
• Age-related macular degeneration Market Drivers and Barriers
• KOL Views
• Age-related macular degeneration Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Age-related Macular Degeneration Market Report Introduction

3. Age-related Macular Degeneration Market Overview at a Glance

4. Age-related Macular Degeneration Market Overview at a Glance

5. Age-related Macular Degeneration Market: Future Perspective

6. Age-related Macular Degeneration Executive Summary

7. Key Events

8. Disease Background and Overview

9. Age-related Macular Degeneration Epidemiology and Patient Population

10. Patient Journey

11. Age-related Macular Degeneration Marketed Drugs

12. Age-related Macular Degeneration Emerging Drugs

14. AMD: Seven Major Market Analysis

15. Key Opinion Leaders’ Views

16. Age-related Macular Degeneration Market Drivers

17. Age-related Macular Degeneration Market Barriers

18. Age-related Macular Degeneration SWOT Analysis

19. Market Access and Reimbursement of Wet AMD

20. Age-related Macular Degeneration Unmet Needs

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

 

Got Queries? Reach out for more information on the Age-related Macular Degeneration Market Research Report- https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/